Eli Lilly stock surges 11% on obesity pill’s success in first late-stage trial
Eli Lilly’s experimental obesity pill, orforglipron, met its main goals in a closely watched late-stage trial, boosting the company’s standing in the fast-growing market for weight loss and diabetes treatments.…
